Latest / CME Outfitters Medical Education / Beyond Symptoms — The Hidden Burden of IBD and the Future of Disease Modification
Transcript
- 0:01SPEAKER_01: Hello, I'm Amar Nayak.
- 0:03SPEAKER_01: On behalf of CME Outfitters, I'd like to welcome you and thank you for joining us for today's podcast entitled Beyond Symptoms: The Hidden Burden of IBD, Inflammatory Bowel Disease, and the Future of Disease Modification.
- 0:17SPEAKER_01: Today's program is supported by an independent educational grant from Merck and Company, Incorporated, Radway, New Jersey, USA, and this activity may include discussions of products or devices that are not currently labeled for use by the U.S.
- 0:31SPEAKER_01: Food and Drug Administration, FDA.
- 0:34SPEAKER_01: The faculty have been informed of their responsibility to disclose to the audience if they'll be discussing off-label or investigational uses, which are any uses not approved by the FDA, of products or devices.
- 0:45SPEAKER_01: Before we begin, I'd like to reread our learning objectives.
- 0:49SPEAKER_01: After listening to our podcast, learners will be able to identify both fibrosis and EIMs or extraintestinal manifestations as distinct but related consequences of chronic inflammatory bowel disease.
- 1:08SPEAKER_01: And evaluate emerging scientific concepts aimed at modifying long-term IBD outcomes.
- 1:15SPEAKER_01: So identify, assess, and evaluate.
- 1:17SPEAKER_01: That's what we'll shoot for today.
- 1:18SPEAKER_01: So I'd like to welcome everyone to episode one of the Hidden Burden of IVD series.
- 1:24SPEAKER_01: Today we're pulling back from the standard symptom conversation to talk about what's happening beneath the surface, so to speak, fibrosis, perhaps, extraintestinal manifestations, and the shared pathways that interestingly connect them.
- 1:38SPEAKER_01: Joining me is Dr.
- 1:39SPEAKER_01: Bruce Sands, Chief of the Division of Gastro Neurology at the ICANN School of Medicine in Mount Sinai.
- 1:44SPEAKER_01: Welcome, Dr.
- 1:44SPEAKER_01: Sands.
- 1:46SPEAKER_00: Nice to be with you.
- 1:47SPEAKER_00: Thank you.
- 1:49SPEAKER_01: So, Dr.
- 1:49SPEAKER_01: Sands, or may I call you call you Bruce?
- 1:53SPEAKER_01: Thank you.
- 1:54SPEAKER_01: When you see a patient with IBD, um who looks fine by every standard symptom measure that that we're that we would potentially think about.
- 2:03SPEAKER_01: But what are you actually worried about that they don't know how to tell you?
- 2:08SPEAKER_00: Well, Amar, of course, I'm delighted when my patient tells me that they're feeling well, but I'm not going to take it at face value because unfortunately what we've learned is what the patient reports is not the whole story.
- 2:21SPEAKER_00: There's a lot of stuff that could be going on that we may not know about unless we investigate further.
- 2:27SPEAKER_00: And we've learned to do that and not just trust what they're telling us.
- 2:32SPEAKER_01: Exactly.
- 2:33SPEAKER_01: That's very interesting.
- 2:34SPEAKER_01: And do you do you feel that that changes as they've had the condition for months or years, or provided we don't have a cure yet for this?
- 2:44SPEAKER_01: Does that kind of education and that prompting, priming make things better, perhaps for us?
- 2:50SPEAKER_00: Yeah, I I think uh what we really want to educate our patients about is the disconnect between symptoms very often and what is going on with the inflammatory state of the disease.
- 3:03SPEAKER_00: Because very often they may be feeling well, and this is perhaps more true in Crohn's disease patients than ulcerative colitis patients, but there still can be this disconnect.
- 3:12SPEAKER_00: They could be feeling perfectly well, and yet you look in with a scope, or you do an intestinal ultrasound, or you do some other tests like fecal cow protectin, and you may find that they actually have active inflammation that's ongoing.
- 3:26SPEAKER_00: And the consequence of that over time is bowel damage, and that's going to affect their quality of life over the long term.
- 3:34SPEAKER_00: They may not realize that initially.
- 3:36SPEAKER_00: So we do need to educate them about this connection between what's going on underneath and how they're feeling.
- 3:43SPEAKER_01: Well, it's interesting.
- 3:44SPEAKER_01: So, Bruce, it's almost like patients can have symptoms and we're looking for those symptoms.
- 3:48SPEAKER_01: And then we have to potentially connect whether those symptoms are a consequence or co-occurrence with inflammation that's active or progressing or improving.
- 3:58SPEAKER_01: And you mentioned some strategies, you know, in terms of testing, intestinal ultrasound, colonoscopy, testing.
- 4:05SPEAKER_01: Is it that any one like the best, or is it a personalized approach that which which to use at what point, or is it kind of a combination of all that?
- 4:14SPEAKER_00: We really use all these tools because the first thing is we want the patient to start responding feeling better.
- 4:20SPEAKER_00: We're talking about the point where they're having symptoms, they're in flair, and they're on that journey toward both symptomatic remission and objective remission of the disease, the disease being quiet.
- 4:33SPEAKER_00: So the first thing is they have to start feeling better.
- 4:35SPEAKER_00: The symptoms have to improve completely, resolve to a state of normalcy.
- 4:41SPEAKER_00: And along the way, we can monitor the inflammation journey by looking at biomarkers.
- 4:48SPEAKER_00: These might be blood biomarkers like C-reactive protein, if they're able to mount that response, or erythrode sedimentation rate, or more specifically, fecal cow protectin, although the barrier to that is patients don't really enjoy submitting stool specimens that often, but they will if they understand why.
- 5:08SPEAKER_00: So that tells you when you see reduction or preferably normalization of those biomarkers that they're headed in the right direction.
- 5:15SPEAKER_00: But that in itself is not enough.
- 5:17SPEAKER_00: At the end of the day, you do want to objectively see by ileal colonoscopy or by cross-sectional imaging if that's what's appropriate for small bowel disease.
- 5:29SPEAKER_00: You want to see that actually the bowel has healed up.
- 5:32SPEAKER_00: So all those tools are needed at different points in the journey.
- 5:36SPEAKER_01: Right.
- 5:36SPEAKER_01: So it's it's almost like a it's like a trust but verify at at intervals that that you'll utilize different members of your treatment team, it seems like, at various points and and build that long-term relationship.
- 5:49SPEAKER_01: Um, it seems to seem to be pretty important.
- 5:51SPEAKER_01: Um, you mentioned something like Crohn's and ulcerative colitis.
- 5:54SPEAKER_01: In this whole concept of disease progression, could could you give us, give me it, give me your take on disease progression with respect to the ulcer of colitis and Crohn's?
- 6:02SPEAKER_01: I'm not I'm not so sure I fully get that, or or anyone everyone else fully comprehends what that potentially means in each of the disease states.
- 6:09SPEAKER_00: Yes, it's a great question.
- 6:10SPEAKER_00: And I think it's easiest to start with Crohn's disease.
- 6:13SPEAKER_00: Of course, all of us have seen patients with Crohn's disease who, at the moment that they're diagnosed, they all already can demonstrate that they have had bowel damage.
- 6:23SPEAKER_00: They may present already with stricture and obstruction, maybe their first presentation.
- 6:28SPEAKER_00: They may present with the perietal fistula.
- 6:31SPEAKER_00: Um, those things can happen from the beginning in a surprisingly high number of patients, which means there's a long preclinical state before they come to diagnosis.
- 6:41SPEAKER_00: And of course, there is another issue of delay in diagnosis, because a lot of people may have vague diarrhea or abdominal pain that just doesn't rise to the level of presenting to a gastroenterologist that leads to the diagnosis.
- 6:55SPEAKER_00: But once you actually do establish the diagnosis, if the inflammation continues without being checked by effective medical therapy, you have gradual accumulation of bowel damage.
- 7:09SPEAKER_00: You have evolution in many patients of stricture.
- 7:13SPEAKER_00: So strictures are a combination of fibrosis, sometimes smooth muscle hypertrophy, but the end result is obstructive symptoms.
- 7:23SPEAKER_00: And eventually, if you don't alleviate that, they'll end up with surgery.
- 7:26SPEAKER_00: And of course, surgery is an irreversible form of bowel damage in a way, although often necessary.
- 7:33SPEAKER_00: Now, in ulcerative colitis, it's it's a little bit different, right?
- 7:38SPEAKER_00: So a lot of patients come to diagnosis faster because there's nothing that's going to make a patient rush to the doctor faster than blood in the stool.
- 7:47SPEAKER_00: That really gets everyone's attention.
- 7:49SPEAKER_00: And so that's of course more common in patients with ulcerative colitis than in Crohn's disease, and that often leads to an earlier diagnosis.
- 7:58SPEAKER_00: There is also this feeling that with ulcerative colitis, the inflammation is much more on or off, whereas in Crohn's disease, it's sort of chronically ongoing.
- 8:09SPEAKER_00: Um, nevertheless, we've learned that there is the capability for bowel damage and fibrosis, even in ulcer of colitis, if you don't control the inflammation.
- 8:20SPEAKER_00: So the chronic inflammation, and of course, by definition, ulcer of colitis is an epithelial inflammation rather than full thickness of bowel, as we see in Crohn's disease, which is why it's more prone to strictures.
- 8:33SPEAKER_00: But still, with chronic inflammation, you see you see submucosal fibrosis, and that leads to loss of function, meaning more stool frequency potentially, more stool consistency, just uh a series of other other kinds of things.
- 8:48SPEAKER_00: And rarely you can have stricture form as well.
- 8:52SPEAKER_01: Wow.
- 8:53SPEAKER_01: Yeah, so that seems uh that's that's fantastic.
- 8:56SPEAKER_01: I love how kind of kind of bringing both those kind of concepts together.
- 8:59SPEAKER_01: I'm understanding that, you know, while also colitis, you know, we talk about superficial inflammation, but things happen beneath the surface um in both disease states that we really um you know kind of put put to importance the amount of treating inflammation and you know, both during induction of remission goals and maintenance, um which frankly it seems like patients spend most of their time, hopefully, in that in that in that latter stage.
- 9:23SPEAKER_01: Um, and not to mention, even though I'm sure we'll get into extra intestinal manifestations, but those can be quite debilitating um in both those condition states.
- 9:30SPEAKER_01: And and we kind of have this um this you know kind of aid that um has really helped kind of bring forth that that difference and bring to the light the conversation of this treat-to-target concept, you know, um the stride um stride one, stride two, and I'm I'm assuming stride three, hopefully soon.
- 9:45SPEAKER_01: Um but stride two gave us gave us something to latch on to and try to try to make sense of all of this this very challenging disease state in terms of giving us a stepwise approach to actually have a framework, right?
- 9:57SPEAKER_01: A treat-to-target framework, looking at symptomatic response, biomarker normalization, healing of the lining of the intestine, endoscopic healing, um, and perhaps even more on looking at trans abdominal ultrasound.
- 10:09SPEAKER_01: But in your practice, um uh how often are you actually getting there?
- 10:13SPEAKER_01: Um, how often can you get and and you set obviously we set the goals, but um, do you do you can in the right patient, how do you decide, you know, what goal, what's good enough, what's great?
- 10:23SPEAKER_01: And I used to have someone always tell me, don't let perfect be the enemy of good, but like how do you develop that personalized care?
- 10:28SPEAKER_01: Give give us the give us the secret sauce.
- 10:31SPEAKER_01: You know, how does this how does it work?
- 10:32SPEAKER_00: Yeah, you you went right to the heart of the matter, which is um really a question that is not quite fully answered by the field yet.
- 10:40SPEAKER_00: So, yes, stride one and two um have held out these treatment targets.
- 10:45SPEAKER_00: These are ideal targets of mucosal healing and symptomatic remission.
- 10:49SPEAKER_00: And yes, maybe in the future we're also talking about transmural healing, uh, particularly in Crohn's disease.
- 10:56SPEAKER_00: Maybe in his uh in ulcerative colitis, we'll really be embracing histologic healing, histologic remission.
- 11:03SPEAKER_00: Um, for a subset of patients, all those things are achievable, but not 100% of patients.
- 11:10SPEAKER_00: So the real tricky thing that you put your finger right on is the patient has improved.
- 11:15SPEAKER_00: So we've seen benefit, they're much better than they were when you started therapy, but what's good enough?
- 11:22SPEAKER_00: Um they haven't quite hit the ultimate target, they haven't completely healed the mucosa.
- 11:28SPEAKER_00: Um, it's it's tricky because uh the one thing that's easy is modifying a drug that they're on.
- 11:36SPEAKER_00: And an example would be InflixMab.
- 11:39SPEAKER_00: So if they're on InflixMab and they're underdosed, you measure a trough level, and you know you're not quite hitting that target, which is a different sort of target, really, then you can dose optimize.
- 11:50SPEAKER_00: It's easy to dose optimize, shorten frequency, increase the dose of medications, and sometimes that alone will get a patient there.
- 11:58SPEAKER_00: What's harder is if there's no room for dose optimization with medication, and the only option, if you really want to get further, is switching to a different uh class of medication.
- 12:10SPEAKER_00: We can never predict, unfortunately, that a patient will do better on the next class of medication.
- 12:18SPEAKER_00: In fact, uh statistically, every time we move from one drug to another, we actually see a decrease in efficacy.
- 12:26SPEAKER_00: So the the field is busy trying to answer the question of what is the most appropriate target?
- 12:33SPEAKER_00: Is it in ulcerative colitis, is it purely endoscopic improvement or is it really histologic level of improvement?
- 12:41SPEAKER_00: And that will be answered in a study called Verdict very shortly.
- 12:46SPEAKER_00: And we will see in another study called Vectors, which is following a target to either endoscopy or to ultrasound transmural healing and Crohn's disease, which which target is the one to optimize for?
- 13:01SPEAKER_01: That's fascinating.
- 13:01SPEAKER_01: I would eagerly anticipate anticipate this, um, and and and hopefully some more clues and and um in terms of you know positioning therapies and and and looking at looking at everything on in inside underneath it all.
- 13:13SPEAKER_01: Um so I get the sense of like uh symptomatic symptom remission.
- 13:18SPEAKER_01: If I had to have you have you give you a 60-second spot to kind of just lay it out in terms of saying symptom remission uh does not equal structural control or control of inflammation.
- 13:28SPEAKER_01: Bruce, you have if you have to make that case to someone in the community um taking care of a challenging IBD patient, um, well, how would you how would you make that case?
- 13:37SPEAKER_01: Hey, you're feeling better, but you know, it doesn't always equal structural control.
- 13:41SPEAKER_00: That's right.
- 13:42SPEAKER_00: I think you know, we all have done colonoscopies on patients who are feeling telling us they're feeling well.
- 13:50SPEAKER_00: Sometimes if you probe a little further, you'll find they have some residual symptoms that they've sort of become acclimated for.
- 13:56SPEAKER_00: They're so used to being so terribly sick that the amount of improvement they've seen is very significant to them, and that's great.
- 14:04SPEAKER_00: Um, but when you look in, you see that they really have not achieved adequate mucosal healing.
- 14:09SPEAKER_00: There's still endoscopic inflammation that's very evident.
- 14:13SPEAKER_00: So I think the first thing is in my practice, um, I will always pull up endoscopic images, uh, pictures worth a thousand words.
- 14:21SPEAKER_00: You show a patient that here are some ulcers here, that's why you have some residual symptoms, or if they don't have symptoms, this is a problem because it's linked to flair, uh, symptomatic flair within the next year.
- 14:36SPEAKER_00: It's linked to surgical risk in ulcerative colitis, it's even linked long term to the risk of colon cancer and ulcerative colitis.
- 14:46SPEAKER_00: So there are multiple reasons that you can tell them you want to get this to heal up better.
- 14:52SPEAKER_01: No, that's great.
- 14:53SPEAKER_01: Controlling inflammation is consequences.
- 14:54SPEAKER_01: What if one of my mentors used to always talk about this now that this and and the silent Crohn's or silent MI and try David Binyan who used to be like, hey, things can progress unchecked if it's silent Crohn's.
- 15:06SPEAKER_01: And uh, and I always got a got a kick out of that, but I think that that's that's that's one of the things it seems like it might help that these things can complain and you're showing the endoscopic inflammation, what lies beneath.
- 15:16SPEAKER_01: It's the and taking it from this the something from Simon and Garfunkel's the sound of silence, right?
- 15:20SPEAKER_01: And and it's deafening, deafening sometimes and seeing it it it the visual evidence.
- 15:26SPEAKER_00: Yeah, yeah.
- 15:26SPEAKER_00: And uh just to put it out there, I mean, another problem is once a patient feels well, often they may believe that, oh, now I can stop my medication.
- 15:35SPEAKER_00: I've been treated.
- 15:36SPEAKER_00: And this is not an infection where you're treating with antibiotics and the infection is gone.
- 15:41SPEAKER_00: So, you know, the analogy we try to draw there is listen, if you had high blood pressure and you achieved the goal blood pressure, you wouldn't be stopping the blood pressure medication.
- 15:52SPEAKER_00: And it's the same thing with IBD, unfortunately.
- 15:54SPEAKER_00: These are not cures.
- 15:56SPEAKER_01: No, of course, of course.
- 15:58SPEAKER_01: Um, so in terms of what's happened behind the surface, you know, that kind of led us to there a little bit by endoscopy and showing inflammation and so forth.
- 16:05SPEAKER_01: So if you could kind of walk us through a little bit of what's actually occurring structurally, systemically, um, going deeper perhaps on even some of this bowel damage concept.
- 16:15SPEAKER_01: Um, you know, people have tried to, you know, utilize Le Mann index and a couple other things to make it more practical.
- 16:20SPEAKER_01: And I don't know if we're there yet, but what's happening at the tissue level?
- 16:23SPEAKER_01: Why doesn't you know inflammation control always solve that, you know, current the current ability of our you know, our therapies?
- 16:31SPEAKER_01: Why is it always solve it?
- 16:32SPEAKER_01: What happens?
- 16:33SPEAKER_00: Yeah, well, it's quite interesting to realize that, of course, not every patient with Crohn's disease evolves to develop a stricture.
- 16:41SPEAKER_00: There seem to be predispositions, genetic and otherwise, that a subset of patients will develop this cicatrizing disease, this uh kind of narrowing of the bowel that will eventually lead to obstruction.
- 16:55SPEAKER_00: It is more common in small bowel Crohn's disease.
- 16:59SPEAKER_00: You see obstructive symptoms more often.
- 17:01SPEAKER_00: Um, that in turn is associated, for example, with the NOD-2 gene, which is still the most powerful genetic predisposition for Crohn's.
- 17:10SPEAKER_00: Not powerful enough that you can use it as a as a test that is going to make a diagnosis of Crohn's.
- 17:16SPEAKER_00: But if you're not too positive, it predisposes you to developing stricturing disease and small bowel disease.
- 17:23SPEAKER_00: So what's going on there is not just inflammation.
- 17:27SPEAKER_00: Uh, strictures, as I think I already said, are often a combination of fibrosis and smooth muscle hypertrophy in the wall of the bowel.
- 17:36SPEAKER_00: And often there is also a contribution of inflammation as well.
- 17:40SPEAKER_00: Of course, if you can treat the inflammation with any of the medications we have that may work, you may open up the bowel enough that it will alleviate some of the symptoms of obstruction.
- 17:50SPEAKER_00: But at some point, when you get enough fibrosis, and it's a matter of time for, you know, different times for different patients, it'll occur at different rates.
- 18:01SPEAKER_00: At some point, that scar tissue is just sort of irreversible.
- 18:05SPEAKER_00: So we need to think of strategies and future treatments that address that issue for this subset of patients.
- 18:13SPEAKER_00: In other words, there are in other fields antifibrotic therapies that, for example, will treat pulmonary fibrosis, liver fibrosis, kidney fibrosis.
- 18:24SPEAKER_00: There are some things coming along there, and we're hoping the same thing is going to come along in Crohn's.
- 18:30SPEAKER_01: That's fantastic.
- 18:31SPEAKER_01: So if I if I had to lay out like a scenario that that some of us may see in practice, you know, a patient with Crohn's has been on infliximab for seven years.
- 18:40SPEAKER_01: Symptoms are controlled, CRP is normal.
- 18:43SPEAKER_01: Do I need to scope her?
- 18:44SPEAKER_01: Bruce, what's your answer?
- 18:45SPEAKER_01: What do you what do you say?
- 18:46SPEAKER_01: Categorically, yes.
- 18:48SPEAKER_00: You know, you can see control of the inflammation in biomarkers, the symptoms could be perfect.
- 18:54SPEAKER_00: It's surprising how often I do a colonoscopy and find lo and behold, there are lots of ulcers, and there's actually not good control.
- 19:02SPEAKER_00: And my concern, again, is that that's just going to evolve over time subclinically, and it won't be clinical until it's too late to actually intervene.
- 19:12unknown: Yeah.
- 19:12SPEAKER_01: The power of silence occasionally.
- 19:14SPEAKER_01: So that structural damage seems can and has proven to multiple times accumulate quietly.
- 19:20SPEAKER_01: Um, and the same perhaps is true systemically.
- 19:22SPEAKER_01: So kind of a transitioning over into the extra intestinal manifestations, you know, where we kind of have our off-to-be potentially armchair armchair quarterbacks for as dermatologists, rheumatologists, and and and lots of you know, borrowing and and and things like that.
- 19:36SPEAKER_01: But but this this occurs.
- 19:38SPEAKER_01: This is real, it seems like, and and we've seen this, you know, up to half, in depending on you know, in some reports of IBD patients develop extra intestinal manifestations, and over a quarter sometimes occur before we figure out that there's intestinal inflammation and get a diagnosis of Crohn's disease or ulcer colitis.
- 19:55SPEAKER_01: Um are your parents are your patients aware of this?
- 19:59SPEAKER_01: You know, um, do the other specialists know this?
- 20:01SPEAKER_01: Have you built that network?
- 20:02SPEAKER_01: Is that worthwhile?
- 20:04SPEAKER_00: Yeah, for in my practice, it's critical to have built those alliances with dermatologists, rheumatologists.
- 20:10SPEAKER_00: In fact, we're very lucky at Mount Sinai to have um a co-clinic with a rheumatologist and a gastroenterologist.
- 20:18SPEAKER_00: And we have a number of examples like that where there is care side by side for patients with these manifestations.
- 20:26SPEAKER_00: I would broaden it even further.
- 20:28SPEAKER_00: You know, if you want to think about the most common extra intestinal manifestation, it's got to be fatigue.
- 20:34SPEAKER_00: Actually, that is exceedingly common.
- 20:36SPEAKER_00: It affects maybe 85% of patients with IBD.
- 20:40SPEAKER_00: And unfortunately, it doesn't always get better when even when the inflammation does subside.
- 20:47SPEAKER_00: So, in a very broad sense, just about every patient is likely to be affected by some extra intestinal manifestation.
- 20:55SPEAKER_01: Oh, yeah, I like that's the uh at a at a at a at a risk of sounding a little risque at point of that.
- 21:01SPEAKER_01: It's the F it's the other F-word, you know, the fatigue, fibrosis, but that's it's that the ultimate quality of life from that.
- 21:07SPEAKER_01: We have a s we have a solution for that.
- 21:08SPEAKER_01: And and people have tried to look at it with scores, and and but I think it's it's such an important thing because over time, unrelenting network of right, I have this intestinal inflammation, I have this going, now I have things outside of my body that are inexplicably to me linked as you know, if I were a patient.
- 21:25SPEAKER_01: So I guess the next the next yeah, the next kind of concept that I that I would wonder if you what you think about is kind of sorting out these extra intestinal manifestations.
- 21:34SPEAKER_01: And if you could sort them out, obviously you could sort them out by like joints and skin and and and things like that, but um and other even the non classic ones, but how about thinking about in terms of activity linked versus activity independent, looking at the degree of inflammation potentially in the intestine and what they may signal?
- 21:50SPEAKER_01: Um how do you how do you kind of go through that in terms of if these extraintestinal manifestations are directly linked to an uncontrolled inflammation in your in your bowel?
- 21:57SPEAKER_01: And how much does it matter in and and how Yeah.
- 22:00SPEAKER_00: Yeah, I think the last point is a good one.
- 22:02SPEAKER_00: Regardless of whether it is linked or unlinked, you have to address it in one way or another.
- 22:09SPEAKER_00: I think we're not fully qualified to answer all those questions.
- 22:14SPEAKER_00: For example, I'll I'll use the eye manifestations.
- 22:17SPEAKER_00: You know, I'm not qualified because I don't have a slit lamp in my office, nor do I know how to use one to differentiate a red eye that is from iritis or uveitis, which is really a medical emergency, or episcleritis or scleritis, um, each of which are a little bit different.
- 22:36SPEAKER_00: Iritis can run a course completely, or uveitis and irritis can run courses completely independent of the bowel inflammation.
- 22:44SPEAKER_00: Um, so similarly, skin manifestations, maybe the most commonest, the most common one is going to be psoriasis.
- 22:52SPEAKER_00: And that's not strictly a manifestation of the bowel disease, it's an association that is quite common, however, that people with IBD are also more commonly predisposed to psoriasis.
- 23:05SPEAKER_00: The classic things that we talk about, the pyodermic gangrinosum, erythema nodosum, those are not terribly common, but you do see them.
- 23:15SPEAKER_00: And to a greater or lesser extent, they are linked to to activity of bowel inflammation.
- 23:21SPEAKER_00: But my experience is uh, you know, for pyodermogangrinosum, often will run a course completely separate.
- 23:28SPEAKER_00: Um, erythema nodosum sometimes runs a course in parallel, sometimes not.
- 23:34SPEAKER_00: And then we have the the arthritis manifestations.
- 23:37SPEAKER_00: The most common things are kind of peripheral joint, small joint, um, arthralgas, not frank arthritis, but you also have axial arthropathies.
- 23:49SPEAKER_00: Those are often not uh not closely linked with the the bowel inflammation activity, uh, but sometimes are even then.
- 23:59SPEAKER_00: Either way, we have to treat them.
- 24:01SPEAKER_00: And usually the principle is we'd like to pick one drug that's going to treat all the manifestations if we can.
- 24:08SPEAKER_00: Sometimes we can't.
- 24:10SPEAKER_01: Yeah, so the concept of bones, bones and crohnes, uh, aside from the damage the steroids do and bone demon demineralization that can occur, and even potentially sometimes independent of that, that there's maybe something going on.
- 24:23SPEAKER_01: Um, and you know, so it's a sense of like understanding.
- 24:26SPEAKER_01: I mean, as gastroenterologists, should we should we know to be like, hey, are you having back pain?
- 24:30SPEAKER_01: Are there stiffness?
- 24:31SPEAKER_01: Are my are my elbows and shoulders hurting?
- 24:33SPEAKER_01: My wrists stiff, um, and and you know, bring that out in terms of asking about it and then referring to your network.
- 24:39SPEAKER_01: And is there inflammation?
- 24:40SPEAKER_01: Is this osteoarthritis, which as as IBD patients are aging, as we're taking care of them longer?
- 24:46SPEAKER_01: I mean that's that's a part of it too.
- 24:47SPEAKER_01: And um, it it seems like at least the knowledge of it initially, at least that it's an occurrence and asking about it maybe maybe kind of our one of the some of the one of the best things we could do.
- 24:56SPEAKER_00: I I think that's right.
- 24:57SPEAKER_00: And this is part of my standard list of questions at every visit is are you having red or sore eyes?
- 25:03SPEAKER_00: Are you having mouth sores?
- 25:05SPEAKER_00: Are you having any new skin rashes or skin lesions of some sort?
- 25:10SPEAKER_00: Are your joints hurting at all?
- 25:12SPEAKER_00: I ask about fatigue always and energy level, um, all these things you can ask.
- 25:18SPEAKER_00: And then there are other uh extraintestinal manifestations that are not going to be manifest in symptoms at all, but you still have to be aware of.
- 25:26SPEAKER_00: Um, you could think of PSC as a linked condition, um, not exactly an extra extraintestinal manifestation.
- 25:35SPEAKER_00: Um bone loss, as you pointed out, is not always from steroids, it sometimes from the disease itself, sometimes it's just familial.
- 25:43SPEAKER_00: Um, but I think personally every patient with IBD ought to get at least one bone density study at some point.
- 25:50SPEAKER_00: Yeah, pretty quickly.
- 25:53SPEAKER_01: Absolutely, absolutely.
- 25:54SPEAKER_01: That sounds like it sounds like a great idea in that sense of and building that building that into your clinical practice kind of platform and expectations with your team, I think that could be really helpful in the community and says that awareness of that and prevent a lot of potential unwanted complications.
- 26:09SPEAKER_01: Um let me let me get you a scenario here in terms of a Crohn's patient and incorporating some of this extra intestinal manifestation.
- 26:17SPEAKER_01: So we let's say we have a we have a 38-year-old man um with Crohn's disease in endoscopic remission on needalismab.
- 26:24SPEAKER_01: He's had three months, there's three months of worsening back pain and three episodes of left-eye redness, none of which have been evaluated, obviously, until he present presents to your client.
- 26:34SPEAKER_01: And he was previously an atolibimap, um stopped, you know, a year and a half ago due to secondary loss of response, let's call it.
- 26:42SPEAKER_01: What's what's going on?
- 26:44SPEAKER_01: Um, what do you do?
- 26:44SPEAKER_01: And how you know, someone who's an endoscopic remission, I guess let's assume it's pretty recent.
- 26:49SPEAKER_01: Um, how do you how do you how do you attack that?
- 26:51SPEAKER_01: How do you approach that?
- 26:53SPEAKER_00: Yeah, well, I I'm assuming that it is a recent look, but if it isn't, you can try to ascertain whether there is now uh inflammatory activity in the bowel.
- 27:04SPEAKER_00: You could do that through blood biomarkers, CRP sed rate, you could do it through fecal cow protectin.
- 27:10SPEAKER_00: If you're lucky enough to have access to intestinal ultrasound, that's very quick and in the office you can know it.
- 27:17SPEAKER_00: Um so there are things that you can do to figure that out and make sure it's still on track.
- 27:21SPEAKER_00: Assuming it is, um, we we often will see that when people go from a systemic therapy like an anti-TNF to a more gut-focused therapy like vetalismab, um, that you may see an unmasking of extraintestinal manifestation systemically.
- 27:41SPEAKER_00: And that may be what's going on here.
- 27:43SPEAKER_00: That even though atolumab, when adolumimab was working, it might have been treating two conditions that were separate, some axial arthropathy, that would be my guess.
- 27:54SPEAKER_00: And the red eye, who knows, but it certainly needs to be evaluated by an ophthalmologist, not by me alone.
- 28:01SPEAKER_01: Yes, yes.
- 28:03SPEAKER_01: Oh, absolutely, absolutely.
- 28:04SPEAKER_01: And and that that that kind of kind of thing goes way was well altogether.
- 28:08SPEAKER_01: So if I if you have to finish the sentence for me, the EIM or my this uh acronym I've made up for extra intestinal manifestation, this EIM or we've made up, I should say, I see most often go unrecognized in community practice is fatigue.
- 28:23SPEAKER_00: Yes, I always think fatigue is the most it's the thing that is most prevalent and often not asked about, but pervasive in a lot of patients.
- 28:33SPEAKER_00: But after that, it's again what's most common is what's most common, it's really joint aches of all sorts.
- 28:42unknown: Okay.
- 28:43SPEAKER_01: It's uh yeah, the uh you're tired of hearing about, tired of not thinking about it and tired of feeling that way in terms of fatigue, but that's a real that's a really big one.
- 28:51SPEAKER_00: And and a lot of these inflammation and all these uncontrolled you know symptoms kind of I I think gastroenterologists are, of course, rightfully focused on the bowel.
- 29:00SPEAKER_00: How's your bowel function?
- 29:02SPEAKER_00: But we should in our IBD patients be thinking sort of systemically, so we have to ask about all these things.
- 29:09SPEAKER_00: And I I think a lot of a lot of patients um don't make the connection themselves, so they don't even think to ask their gastroenterologist, right?
- 29:17SPEAKER_01: I like that.
- 29:18SPEAKER_01: I like that.
- 29:18SPEAKER_01: I I just I heard one thing, one thing, and think systemically.
- 29:22SPEAKER_01: Think about the whole patient.
- 29:24SPEAKER_01: Um, that's wonderful.
- 29:25SPEAKER_01: Uh just right there.
- 29:26SPEAKER_01: That that sums it up.
- 29:28SPEAKER_01: But that case like connect, I think that case that of that patient who was on vitalism map after a limit map failure, it connects us directly to that clinical trap.
- 29:37SPEAKER_01: Uh, you know, much like my my Star Wars you know feed, it's a trap in terms of coming to Admiral Bar coming in.
- 29:42SPEAKER_01: It's a trap.
- 29:43SPEAKER_01: Uh, you know, and what does you know that clinical trap does the most harm?
- 29:46SPEAKER_01: But you know, you can you can rally and just like they did and and understand some of these things that are occurring with this unmasking effect.
- 29:52SPEAKER_01: You know, what does this happen?
- 29:54SPEAKER_01: How often does this happen?
- 29:55SPEAKER_01: Are you prepared for it?
- 29:56SPEAKER_01: Kind of um or or afterwards?
- 29:58SPEAKER_01: Is this is this the benefit of having close follow-up after induction in other therapies?
- 30:03SPEAKER_01: What do you do?
- 30:04SPEAKER_00: Yeah, when uh well I think whenever I'm changing a therapy, I'm really following the patient very carefully to make sure that they're responding, uh, that they're maintaining that objectively and subjectively they're they're doing okay.
- 30:19SPEAKER_00: Um, and I think this um anti-TNF unmasking, or you know, it happens when you stop an anti-TNF, or when an anti-TNF starts working.
- 30:29SPEAKER_00: That could be another clue that the patients developed anti-drug antibodies to the anti-TNF, suddenly they start having joint manifestations, and you're not sure why.
- 30:39SPEAKER_00: Um, it could simply be that they've developed anti-drug antibodies and have inadequate levels of the drug.
- 30:45SPEAKER_00: That's another sort of unmasking, really.
- 30:48SPEAKER_00: And so in my practice, I'm sort of watching carefully as they switch.
- 30:54SPEAKER_00: I don't anticipate that every patient who comes off an anti-TNF and goes on another therapy is instantly gonna erupt in a new extra intestinal manifestation, but my guard is up.
- 31:06SPEAKER_01: Yeah.
- 31:07SPEAKER_01: So it's not so much the biologic, the next biologic or the next one therapy causing the extraintestinal manifestation, more of just the previous one, perhaps may have been suppressing it and that mistake can sometimes throw people off, you know, and and it's in that complexities.
- 31:20SPEAKER_00: That that's right.
- 31:21SPEAKER_00: And the thing about TNF is it it is a very important cytokine.
- 31:26SPEAKER_00: It downright, you know, it's implicated in all kinds of inflammation, immune-mediated inflammation, and a lot of different processes, which is why it's used to treat psoriasis and psoriatic arthritis and ulceropclitis and Crohn's disease, all these different conditions.
- 31:43SPEAKER_00: Um, so it makes sense that when you pull back from that, other things are going to come up when we know that these patients are predisposed to these other conditions.
- 31:52SPEAKER_00: And similarly, there are other important cytokines that can be thought of as sort of master cytokines that might also control systemic effects.
- 32:02SPEAKER_00: An example of that would be TL1A, which is a member of the TNF superfamily, but very different from it.
- 32:09SPEAKER_00: And we could talk about that some more.
- 32:11SPEAKER_00: It really TL1A was found to be implicated in uh as a risk factor for Crohn's disease in Asian populations, East Asian GWAS studies, genome-wide association studies, was powerful in a way that not too is powerful in Caucasian populations with Crohn's disease.
- 32:31SPEAKER_00: Um, but it turns out TL1A is elevated uh in the inflammation of IBD uh no matter where the patients are in East Asia or any other part of the world.
- 32:43SPEAKER_01: Oh, that's fascinating.
- 32:45SPEAKER_01: I mean, we we have a shared pathway picture, and you kind of transitioned perfectly on Dread My Mind and looking at IL-23, TL1A, Jack Staten, um thinking about this shared pathway and explaining that to somebody who's thinking of IBD, just a bowel disease.
- 32:58SPEAKER_01: I think you hit the nail of the head in terms of all the other areas in the body where inflammation is impactful and our are, you know, immune modulation, so to speak, these targeted immune modulations have have downstream effects, and hopefully many of them very positive, although we've seen some negative ones potentially, which have been probably clues as to how things have worked.
- 33:16SPEAKER_01: And this chronic activation of tissue remodeling to structural damage, their systemic spillover.
- 33:23SPEAKER_01: Um does this part of the logic combining this to Hammond or another F-word here, fibrosis, and there's been, you know, some of our colleagues have done you know really fantastic preliminary work and exciting, hopefully new therapies upcoming for antifibrotic therapies.
- 33:38SPEAKER_01: And perhaps if there's fibrosis laying down as part of an injury during inflammation and ulcer, ulcer formation, which you know, ulcers we know from they occur everywhere in it in the stomach and everywhere else and bend to Bibb, and there's an element of fibrosis and tissue remodeling there.
- 33:51SPEAKER_01: Is there any logic comparing those that develop fibrosis?
- 33:56SPEAKER_01: Is it just a sense of inflammation over time leading to extraintestinal manifestations?
- 34:00SPEAKER_01: Is is is TL1A potentially an angle here?
- 34:03SPEAKER_01: Um, what are what are some what are some ways that we could start thinking about fibrosis, EIMs, TL1A, um, and and looking at you know entrance?
- 34:12SPEAKER_00: Yeah, it's a massive web of connected things.
- 34:15SPEAKER_00: So all the cytokines and cell types are uh interacting with each other.
- 34:19SPEAKER_00: In fact, cytokines are how different cells communicate with each other in the sense, and that inflammatory process in the bowel, obviously, there's release of cytokines elsewhere.
- 34:31SPEAKER_00: There are migration of cells from the inflamed bowel to other affected areas, for example, maybe to skin, maybe to eye, maybe to um, you know, your lower back where you're having pain.
- 34:43SPEAKER_00: So there is this spillover.
- 34:46SPEAKER_00: And at the same time, you're getting, if there is ongoing inflammation, you can get in some patients, not all, this deposition of fibrosis, scarring, uh, stricturing disease.
- 34:58SPEAKER_00: Um, so you know, again, there are interesting links there in a general sense.
- 35:02SPEAKER_00: In a specific sense, uh, one cytokine that seems to link uh all these things potentially might be TL1A, uh, because we know that it drives intestinal inflammation.
- 35:13SPEAKER_00: It also is implicated in non-intestinal inflammation uh for in other conditions, and it also is separate from the uh inflammatory component.
- 35:24SPEAKER_00: It also independently drives fibrosis.
- 35:27SPEAKER_00: So it really spans everything in terms of what it can do in terms of uh provoking inflammation and provoking fibrosis and stricture, and what it could do for systemic manifestations extraintestinally.
- 35:44SPEAKER_01: You know, I think it's fascinating to think about.
- 35:46SPEAKER_01: We have a long-term condition and looking at disease duration, symptom duration, extraintestinal manifestation, the length of inflammation, and I don't know, do you think there's a connection potentially in those who you know have that extra intestinal manifestation prior to their IVD diagnosis and things have kind of run amok for a while versus getting things under control?
- 36:07SPEAKER_01: Is there usually a time point that you say, like, hey, these expected extraintestinal manifestation symptoms, you would have expected them to be better at some point, and they have a natural variance of up and down in terms of how things form.
- 36:20SPEAKER_01: Um, do you see anything different with or expect anything different from from TL1A or or other therapies that that you've seen or how or disease progression or disease natural history, which we really haven't talked too much about, but of inflammatory bowel, which can differ.
- 36:34SPEAKER_00: So that's I think it's very clear that for fibrosis, um, time is a major factor.
- 36:41SPEAKER_00: It's not as clear to me with extra-intestinal manifestations, but I just have this general sense that the longer you go with poorly treated or untreated bowel inflammation, the more likely you are to see this spillover in these extraintestinal organs that lead to these other manifestations.
- 37:00SPEAKER_00: So, in that sense, I think duration matters for both of these things.
- 37:04SPEAKER_00: And you you alluded to um upcoming therapies, things that are in phase three trials now, that are anti-TL1A antibodies.
- 37:14SPEAKER_00: Uh, tulosokobard is one of these, but there are two others, a fimcobard and dubacetug.
- 37:20SPEAKER_00: Um, all of them, in one way or another, are antibodies directed at uh neutralizing TL1A, which prevent it from interacting with its receptor, which then should downregulate inflammation and in theory at least should downregulate fibrosis too.
- 37:37SPEAKER_00: And because their systemic exposure with the uh with the agent should also uh should, in theory, treat extraintes manifestations of different sorts.
- 37:48SPEAKER_00: Now, we have a lot of evidence from the phase three studies that these are uh very effective agents for treating bowel inflammation in both Crohn's and in ulcerative clitis.
- 37:59SPEAKER_00: We're hopeful about the antifibrotic effect, but that just turns out to be harder to demonstrate in a clinical trial.
- 38:06SPEAKER_00: So it's going to take longer to show that.
- 38:08SPEAKER_00: And I'm sure in the course of these phase three trials, there will inevitably be patients with extraintestinal manifestations, and we will learn in the course of these studies how they fare.
- 38:18SPEAKER_00: And I think the early information is that they actually do pretty well.
- 38:23SPEAKER_01: I like it.
- 38:24SPEAKER_01: Thinking systemically, and and the other thing you mentioned, you know, a few minutes back is understanding that patient who presents with a stricture, a Crohn's patient presenting with a stricture or and kind of kind of going getting the DeLorean and going back in time and seeing how that potentially developed prior to this occurring.
- 38:40SPEAKER_01: Um, maybe there's some more clues there.
- 38:42SPEAKER_01: But if I had to if I had to say another, if you had to drop another clinical pearl on us, you know, tell us something.
- 38:48SPEAKER_01: What's the one thing community gastroenterologists most often fail to act on or have find themselves unable to act, I should say, when it comes to the hidden burden of IBD?
- 38:58SPEAKER_00: Well, I I think the first thing is to realize that that burden is there, even if it's hidden, and to look for it.
- 39:06SPEAKER_00: Um, just look for it.
- 39:07SPEAKER_00: Go beyond the symptoms themselves.
- 39:10SPEAKER_00: And the next the next thing is um not to ignore it when you find it.
- 39:16SPEAKER_00: You know, when you see ongoing inflammation, you should try to tweak the treatment within reason.
- 39:21SPEAKER_00: If it's dose modification, great.
- 39:24SPEAKER_00: If it's changed to another therapy, if uh the residual inflammation rises to the level requiring change, then you have to be brave and do it and explain to the patient why.
- 39:36SPEAKER_00: Because if the patient is not your ally in this journey, they're they're not going to go for it.
- 39:42SPEAKER_01: Oh, excellent.
- 39:43SPEAKER_01: I'm gonna give you some rapid fire, uh, just a few rapid fire.
- 39:46SPEAKER_01: Give me your your first instinct um and and in terms of how this feels.
- 39:50SPEAKER_01: It's like a okay, I have a patient, normal CRP, elevated fecal cal protectin, minimal symptoms.
- 39:55SPEAKER_01: Reassured or concerned?
- 39:57SPEAKER_00: Very concerned and probably gonna look for objective confirmation that um, assuming it's not an infection, uh intercurrent infection, I would probably, in short order, scope that patient.
- 40:09SPEAKER_01: Okay.
- 40:11SPEAKER_01: Antifibrotic therapies for IBD, five years away or more than five?
- 40:16SPEAKER_00: Uh I think it's uh five years or less if you think that the anti L1As are antifibrotic.
- 40:22SPEAKER_00: Of course, proving that is going to take a little while.
- 40:26SPEAKER_01: Crohn's disease patient, two steroid courses in three years, fibrosis risk, low, medium, or high.
- 40:34SPEAKER_00: High, because I don't think steroids are long-term effective therapy.
- 40:38SPEAKER_00: You haven't told me that the patient is on anything else.
- 40:41SPEAKER_00: Um, I think that patient needs an advanced therapy that's effective.
- 40:45SPEAKER_01: Excellent.
- 40:46SPEAKER_01: TL1A as a new therapeutic target, incremental paradigm shifting?
- 40:53SPEAKER_00: I want to believe it's paradigm shifting.
- 40:55SPEAKER_00: I do think it's different from anti-TNF.
- 40:58SPEAKER_00: It I told you it's in the TNF uh superfamily of molecules, but it's very different.
- 41:03SPEAKER_00: And actually, most importantly, I didn't say this, it's not broadly immune-suppressing in the way that we see with anti-TNFs with risk of infection, some risk of lymphoma, and so on.
- 41:14SPEAKER_00: We we do not anticipate seeing that, and so far we haven't seen that with any of the anti-Tel1As.
- 41:20SPEAKER_01: I'm gonna add an add you another little different odd one, and let's just assume that everything I say is correct.
- 41:25SPEAKER_01: Fibrosis confirmed on MRE.
- 41:27SPEAKER_01: Let's pretend strictures, um, symptoms minimal, CRP normal, change therapy, stay the course.
- 41:32SPEAKER_01: What do you do?
- 41:34SPEAKER_00: You probably will stay the course as long as they're not having obstructive symptoms and the inflammation is well controlled.
- 41:42SPEAKER_00: Um, that's probably the best you can do.
- 41:44SPEAKER_00: Once they start having symptoms, though, and it's still fibrotic, then you need a physical approach.
- 41:50SPEAKER_00: Either it's going to be balloon dilation or strictoplasty or resection.
- 41:55SPEAKER_00: The thing I wish every new IBD patient understood about their disease before we started treatment is they need to be on their treatment, maybe not forever, but they need to be on a treatment for the foreseeable future.
- 42:11SPEAKER_00: And that it's great to feel good, but we also want to prove that you're as good on the inside as you are on the outside.
- 42:19SPEAKER_01: Excellent, excellent.
- 42:20SPEAKER_01: I love that.
- 42:20SPEAKER_01: Good on the as good on the inside as you are on the outside.
- 42:23SPEAKER_01: I love that.
- 42:25SPEAKER_01: Look, the science is moving fast, and we kind of alluded to this as maybe the next five years, um, things are going to be even even more substantially uh advanced in these antifibrotic targets are in preclinical, early phase, treat-to-target evolving towards transmural healing, perhaps.
- 42:41SPEAKER_01: TL1A is that shared pathway um target.
- 42:44SPEAKER_01: You know, where does where does IBD management look like in five years?
- 42:47SPEAKER_01: If this pipeline delivers, right?
- 42:49SPEAKER_01: Obviously that's that's what we're hoping, but we think, but what's the single that?
- 42:52SPEAKER_01: And then what's the single most important thing?
- 42:54SPEAKER_01: What can what can clinicians do right now before these tools exist to protect their patients, to to take good care of patients?
- 43:02SPEAKER_00: You know, before these tools exist, even now we have very effective therapies, and I think it's very important to realize that a lot of newly diagnosed patients go a very long time before they ever see one of these more effective therapies.
- 43:16SPEAKER_00: Even anti-TNFs are extremely effective, especially when used early, soon after the diagnosis.
- 43:24SPEAKER_00: So maybe a very key thing that everyone could do is getting the patients on effective therapy right from the get-go, not multiple trials of steroids and uh step therapy upwards that takes years.
- 43:39SPEAKER_00: Um we really should treat really uh to an effective degree, subjectively, objectively, early in the course of the disease.
- 43:50unknown: Okay.
- 43:52SPEAKER_01: If you have to finish a sentence, the thing that would most change how IBD patients are managed starting tomorrow.
- 44:00SPEAKER_01: You've you've got the uh Bruce Almighty, um, kind of you know, taking my gym channel starting tomorrow, everyone's gonna do exactly what you're gonna tell us to do.
- 44:09SPEAKER_01: Um that would most change how IBD patients are married are managed.
- 44:12SPEAKER_01: What would it be?
- 44:14SPEAKER_01: Treat effectively early and treat to target.
- 44:17SPEAKER_01: I like it.
- 44:18SPEAKER_01: Treat effectively early, treat to target.
- 44:20SPEAKER_01: Fantastic.
- 44:21SPEAKER_01: Um well, thank you.
- 44:22SPEAKER_01: Thank you, Bruce, Dr.
- 44:23SPEAKER_01: Sands.
- 44:23SPEAKER_01: To our learners out there, um IBD is not just a bowel disease, even though it shares the B.
- 44:29SPEAKER_01: Um it's a systemic, think systemically, systemic progressive disease that causes structural scarring, extra intestinal complications, and silent inflammation that symptoms uh won't always reveal, will not reveal.
- 44:42SPEAKER_01: Treat the target, monitor beyond symptoms, and recognize what your patient isn't telling you.
- 44:47SPEAKER_01: You know, that might be the most important part of the story.
- 44:50SPEAKER_01: Uh and with that, I'll share a few um smart uh goals to put information into action.
- 44:56SPEAKER_01: And when you get back to your practice, I'll try to one, increase the proportion of IVD patients assessed for structural disease burden and extraintestinal manifestation status at each visit using objective measures and not just the symptom report only alone.
- 45:12SPEAKER_01: And also to improve recognition of intestinal fibrosis and EIM or extraintestinal manifestation status as active clinical concerns that warrant monitoring and documentation alongside gut disease activity.
- 45:25SPEAKER_01: And last but not least, apply that shared immune pathway concept to evaluate whether current therapy addresses both intestinal disease and a patient's potential systemic manifestations and refer, refer and escalate when these gaps exist.
- 45:41SPEAKER_01: So we have some additional goals for increased professional communication and collaboration, which multidisciplinary teamwork, teamwork makes a dream work, sure.
- 45:48SPEAKER_01: So include establishing clear communication channels, a commitment to evidence-based practices, expressing respect for other healthcare professionals' knowledge and contribution to care, assessing collaboration, competency, um, and willingness to accept feedback from other healthcare practitioners, and then make sure our patient, our caregiver values, our preferences, our needs are concerned by all healthcare professionals, patient-centered.
- 46:14SPEAKER_01: Um, and then again, you know, use a framework for structured communication.
- 46:19SPEAKER_01: For additional resources, visit www.cmeoutfitters.com for clinical information and certified educational activities and the virtual education hub.
- 46:30SPEAKER_01: To receive CME or CE credit for this activity, participants must complete the post-test and evaluation online, and participants will be able to download and print their certificate immediately upon completion.
- 46:41SPEAKER_01: And remember, this is the first of a three-part podcast series on IBD inflammatory bowel disease.
- 46:47SPEAKER_01: I'm also hosting two initial episodes fibrosis and IVD, pathogenesis, risk stratification, and objective monitoring, as well as extraintestinal manifestations and IVD screening, referral triggers, and multidisciplinary care pathways.
- 47:03SPEAKER_01: And I hope you'll be able to join us.
- 47:05SPEAKER_01: Thank you, and uh, we'll see you next time.